Mubadala Investment Company agreed to acquire €200 million (US$235 million) worth of Hamburg-based Evotec shares in a private placement, giving the United Arab Emirates sovereign wealth fund a 5.6% stake in one of Germany's top life sciences firms.
Novo Holdings kicked in an additional €50 million (US$58.8 million) in the offering. But Novo is a longtime Evotec investor that brought its stake in the company up to 11% with the transaction, so the headline news here is Mubadala's increasing eagerness to play the biotech trade.
Mubadala CEO Khaldoon . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.